Physician profile
Daniel Gutierrez
NPI 1720440944
$1,391.04
in general payments reported to CMS, 2019-2025
10 companies · $327 in 2025
The $327 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $97.33 · 2023: $517 · 2024: $449 · 2025: $327.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,273 · Education: $20.58.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,273.13 |
| Education | $20.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $289.62 | 2023 | Vtama |
| Abbvie INC. | $264.34 | 2023-2024 | |
| E.R. Squibb & Sons, L.L.C. | $152.03 | 2024 | Sotyktu |
| Janssen Scientific Affairs, LLC | $144.05 | 2025 | Tremfya |
| Galderma Laboratories, L.P. | $140.47 | 2025 | Nemluvio |
| Janssen Biotech, INC. | $130.01 | 2024 | Tremfya |
| Pfizer INC. | $112.00 | 2023 | |
| Allergan, INC. | $97.33 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $42.72 | 2025 | Dupixent |
| Ucb, INC. | $18.47 | 2024 | Bimzelx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Gutierrez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.